EYAS AL MOUSA
Date Prepared: 2/ 2009
'Curriculum Vitae'
Name:			Eyas N. Al-Mousa, M.D.
Current Position:		 Senior Interventional Cardiologist- Private Sector-9/2005 to present			
				- Associate Clinical Professor. Jordan University Hospital. Amman,
Formerly- General Director .  Al Istiklal Hospital( 5/2006-3/2008)
Address:			P. O. Box: 13075
Jordan University Hospital
Amman, Jordan 11942
Telephone number:		962-6-5001016
				5001000( EXT 262)
				962-777-963000 (mobile)
Fax Number:			962-6-5698833
E-Mail Addresses:		eyasalmousa@hotmail.com
				ealmousa@istisharihospital,com
				eyas@eyasalmousa.com
				cardiology@istisharihospital.com
Education:
1988			M.B.B.S., University of Jordan, Amman, Jordan
1988-1989		Rotating Internship, University of Jordan Hospital
1989-1990		Resident in Medicine, University of Jordan Hospital
1990-1993		Resident in Medicine, Baylor College of Medicine Affiliated Hospitals (The Methodist Hospital, St Lukes Episcopal Hospital, Ben Taub General Hospital and the Houston VA Medical Center).  Houston, Texas.  USA.
1993-1996		Clinical Fellow in Cardiology, University of Texas Affiliated Hospitals ( Hermann Hospital, LBJ General Hospital, MD Anderson Cancer Center, Houston Northwest Hospital and the Texas Heart Institute).  Houston, Texas. USA
1996-1997	Clinical Fellow in Advanced Interventional Cardiology, Harvard Medical School, West Roxbury VA Medical Center/ Brigham and Womens Hospital Program, Boston, Massachusetts. USA
Experience:			
9 /1997- 9/2005		Director  of Cardiology   
Associate Professor of Medicine and Cardiology
Jordan University Hospital
1/2006-5/2006		Director of Medical Services.	Al -Istiklal  Hospital
1993			Diplomate, American Board of Internal Medicine
1996			Diplomate, Jordanian Board of Internal Medicine
1997			Diplomate, American Board of Cardiovascular Medicine
1998			Diplomate, Jordanian Board of Cardiovascular Medicine
2009			Certified Surveyor. Jordan Health Card Accreditation Council
Major Committee/Board  Assignments:
1997 and 2003		Member of the National Committee for Preventive Cardiology Guidelines in Jordan.
1997-present		Member of review board for Jordan Medical Journal and Damascus medical Journal
1998-Present		Member of the Scientific/ Executive Cardiology Committee of the Jordanian Medical Council - Jordan Cardiology Board
1999			Member of the Scientific/ Executive Committee of Jordan Sports Medicine Council
2002			Member of Jordan University' President- appointed committee to reform Jordan University Hospital
2004	Executive and international editorial board, Pan Arab Medical Journal                                                                                                    Chair, CPR committee.  Jordan University Hospital
2005	Chair, cardiovascular committee of Jordan national drug formulary
Professional Societies:
1990			American College Of Physicians
1993			American College Of Cardiology 
2004			Jordanian Cardiac Society
2004			Jordan Lipid and Hypertension Society
Major Research Interests:
1.	Mechanisms of LDL Oxidation
2.	Utilization of Trans-esophageal Echocardiography in I.C.U.
3.	Glycoprotein IIb/IIIa Role in Coronary Interventions
4.	Newer Revascularization Devices
5.	Assessment of Coronary Flow Using TIMI Frame Count Methods
6.	Angiographic Predictors of Clinical Events in Interventional Cardiology
7.	Coronary Ectasia in Jordan
Research Experience:
Mechanisms of LDL Oxidation:  Research Resident with M. Lenz, M.D.  and J. Guytone, M.D. Role of monocyte-lipoxygenases in oxidative modification of LDL.  Lipid research laboratory, Baylor College Of Medicine, Houston, Texas.
6 months of specialized training in the utilization of Trans-esophageal echocardiography in ICU/ CCU settings and the use of stress echocardiography testing.  Echocardiography Lab.  LBJ Hospital, University of Texas. Houston,Texas.
Associate Director, TIMI Angiographic Core Laboratory, West Roxbury VA Hospital, Boston, MA.  Responsibilities include conducting and administrating research  projects, angiographic data acquisition, data analysis, manuscript preparation and review for several multi-center clinical trials including:
-TIMI 10-B Trial (TNK-tPA vs tPA in acute myocardial infarction).
-Restore Trial ( MK-383 + Heparin vs Heparin alone post PTCA).
-Schneider Free flow perfusion balloon comparative trial.
-IVAT( Intermediate Vessel Atherectomy Trial ).
-Schneider wall stent in peripheral vessels Trial.
-Schneider wall stents in coronary arteries Trial.
Sub- investigator in the MK 383 in Unstable angina/ Non Q wave MI Trial, West 	Roxbury VA medical center, Boston, Massachusetts
1997-date (Current work in progress):
	-Principle investigator of the study of Coronary Ectasia In Jordanians
-Participated in a Phase 4 Multicenter study of Enoxaparin in acute coronary syndromes
	-Principle investigator of the Study of Silent Ischemia in Jordanian Diabetics
	-Principle investigator of the study of alternate day statin use in Jordanians
-Principle investigator of the study of Atorvastatin/ Amlodipine ( The GEMINI-AALA) Pfizer study in Jordan University hospital 2004
2003	-Founding Member of JCC-Jordan Collaborative Cardiologists group for     research(Current projects listed  at eArabDoctors.com)
Miscellaneous Courses:
Cardiac Auscultation Course, W. Proctor Harvey, MD.  1995, Houston, Texas.
Intermedics Pacemaker Didactic Course, 1995.
Texas Heart Institute, Peripheral Vascular Interventions`Course, 1995.
Texas Heart Institute, High Risk Coronary Interventions`Course, 1995.
Texas Heart Institute, Heart Transplant Symposium, 1995.
Scimed Preceptor Training Program In Intravascular Ultrasound, 1996.
Palmaz- Schatz Stent Certification Course 1996
Montreal Heart Institute, Interventional Cardiology Fellowship Course, 1996. 
Directional Coronary Atherectomy Basic Training Course (Guidant Inc), San Jose, California ,1997
	Cardiology Review Course, Harvard Medical School, Boston, Massachusetts 1997
	Numerous Meetings of AHA, ACC, TCT, ETC, PCR, ESC...etc
Bibliography:
Original Reports:-
1.Lozano P, Al-Mousa E, et al.  Intra-aortic Thrombus Producing Embolic Arterial Vascular Disease.  Images in Cardiovascular Medicine.  Circulation. 1996;93:1471.
2.Dotani I, Dodge JT, Goel M, Al-Mousa EN, et al.  Techniques in the Angiographic Analysis of Coronary Flow.  J Interven Cardiol 1996;9:429-444
3.Gibson CM, Dodge JT Jr, Goel M, Al Mousa EN, et al.  Angioplasty Guide Wire Velocity: A new Simple Method to Calculate Coronary Blood Velocity and Flow.  Am J Cardiol 1997 Dec 15, 80(12):1536-9
4.Al-Mousa EN, Dodge JT Jr, Rizzo M, et al.  Thrombolysis in Myocardial Infarction Frame Count in Saphenous Vein Grafts.  Am Heart J 1999 Feb;135(2Pt 1):323-8 .(This articles has the first  published reference values for the normal TIMI Frame Counts in vein grafts).
5.Eyas Al-Mousa.  Coronay Ectasia With In- Situ Thrombosis- A Case Report. Jordan Medical Journal. vol.37(1). May 2003. 
6.Eyas Al-Mousa.   Coronary Steal syndrome induced by unclipped LIMA branches -Case Report. Jordan Medical Journal , vol.37(2). November 2003.
7.Eyas Al-Mousa,  , Yahya Ismail,  Jamila AbuDheil, Munir Zaqa. Coronary Ectasia in Jordanians. Epidemiological features, prognosis,  and a proposed new classification. Jordan Medical Journal vol.38(1). May 2004
8. Ayman J. Hammoudeh and Eyas Al-Mousa.  Survey of Jordanian Physicians Management of Dyslipidemia in Patients with Cardiovascular Diseases and Diabetes.   Jordan Medical Journal vol.38(1). May 2004
9.Randa Al-Ahmad, Azmi Mahafzah, Eyas Al-Mousa,  Immunological Changes in Acute Myocardial Infarction.  Saudi Medical Journal.  2004, vol. 25, no7, pp. 923-928
Jordan Collaborating Cardiology Group
The Jordan Hyperlipidemia And Related Targets Studies
1.	The JoHARTS investigators.   Prevalence of conventional cardiovascular risk factors in Middle Eastern patients with coronary heart disease: The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 2). International Journal of Cardiology 2006;110:179-183.
2.	The JoHARTS investigators.   Is dyslipidemia among diabetics in the Middle East different from that in the West? The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 3). Clinical Diabetes Middle East 2006;3:128-131
3.	The JoHARTS investigators. Prevalence of conventional cardiovascular risk factors in Middle Eastern patients with coronary heart disease: The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 2). European Heart Journal 2005,26 (suppl):45.
4.	The JoHARTS investigators. Is dyslipidemia among diabetics in the Middle East different from that in the West? The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 3). European Heart Journal 2005, 26 (suppl):495.
5.	The JoHARTS investigators Dyslipidemia in 5000     Jordanians with and without coronary artery disease.   The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 3). In press
6.	The JoHARTS investigators.   Prevalence of low levels of high-density lipoprotein cholesterol (HDL-C) among 5000 Jordanians: The Jordan Hyperlipidemia And Related Targets Study (JoHARTS-4). Pan Arab Medical Journal, in press
7.	The CAPRIS investigators. Is high-sensitive C-Reactive Protein an independent predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome? CRP and prognosis in acute coronary syndrome. European Heart Journal 2007; 28 (suppl): 595.
8.	The CAPRIS investigators. Is high-sensitive C-Reactive Protein an independent predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome? CRP and prognosis in acute coronary syndrome. International Journal of Atherosclerosis, in press.
9.	The SMART registry investigators. Are there gender disparities in the treatment of Non-ST elevation and ST-elevation acute coronary syndromes in the Middle East? Observations from the SMART registry. European Heart Journal 200;28 (suppl):  94.
10.	JCC Group. Adherence to acute coronary syndrome therapy guidelines in a large Middle Eastern Population. Observations from the survey of management and assessment of coronary heart disease patients (SMART survey). European Heart Journal 2007; 28 (suppl):595.
11.	The JCC group. Utilization of reperfusion therapy in the Myocardial Infarction Triggers and Onset in JoRdan (MINTOR) Study. International Journal of Cardiology 2007;122:156-157.
12.	JoHARTS Investigation group. The Jordan Hyperlipidemia And Related targets Study (JoHARTS): Summary and Implications (part 1). in press.
13.	JoHARTS Investigation group. The Jordan Hyperlipidemia And Related targets Study (JoHARTS): Summary and Implications (part 2). Middle East Medical Journal, in press.
14.	JoHARTS Investigation group. The Jordan Hyperlipidemia And Related targets Study (JoHARTS): Summary and Implications (part 3). Middle East Medical Journal, in press.
15.	JoHARTS and JCC Groups Investigators. Prevalence of diabetes mellitus in large acute coronary syndrome studies in a Middle Eastern country: The road to "GLORY". Clinical Diabetes Middle East Medical Journal, in press.
16.	MINTOR Investigators. Triggers and time of onset of acute myocardial infarction in the Middle East. Myocardial INfarction Triggers and Onset in JoRdan (MINTOR) Study. International Journal of Cardiology, 01/12/2007; 122(2):156-7.
Review Articles:
1.	C. Michael Gibson , Eyas N. Al-Mousa., and Thomas Levin.  Characteristics of thrombolytic agents.   Up to date. 	On CD-ROM.  UpToDate Inc. 1997-date.
2.	Gibson CM, Moynihan JL, Al-Mousa EN, Campsey M, Gandhi R, Murphy S, Mattson S, Ryan KA, Mesley R, Swanson J, Arshad MN, Marble SJ .  Glycoprotein IIb/IIIa Receptor Inhibition in Interventional Cardiology. J Thromb Thrombolysis 1999 Jun;7(3):287-302 
3.	Eyas N. Al-Mousa.  Diabetes and Coronary Artery Disease. Pan Arab Medical Journal  volume 1, March 2004
4.	Amar Salam and Eyas Al-Mousa.  Resuscitation Update.  ( accepted for publication, Jordan Medical Journal 4/ 2004)
5.	Amar Salam and EyasAl-Mousa. The potential role of ximelagatran to become the anticoagulant of choice in Medicine.  Expert opinion in pharmacotherapy.  June 2004
Abstracts:
1.	Gibson CM, Goel M, Dotani I, Rizzo MJ, McLean C, Martin NE,  Al -Mousa EN,  Marble SJ,  Daley WL,  Dodge T.  The Post PTCA TIMI Frame Count and Mortality in RESTORE.  Circulation 1996;94(8):I-85
2.	Gibson CM, Dotani I, Goel M, McLean C, Rizzo MJ, Lis  J, Martin NE, Marble SJ, Al-Mousa EN, Dodge T,  Daley WL, Ross AM.  Flow Improvement Following Intracoronary Stent Placement.  Circulation 1996;94(8):I-453
3.	Gibson CM, Daley WL, Rizzo MJ, McLean C, Martin NE, Dotani I, Al-Mousa EN Goel M, Marble SJ, Dodge JT.  Flow  Following PTCA For Acute MI.  Circulation ;1996:94(8):I-670
4.	Ryan KA, Rizzo MJ, McLean, Dotani I, Goel M, Marble SJ, Al-Mousa EN, Daley WL Dodge T.  The  Relationship Between Dissection Grade & Coronary Blood Flow as well as Other Angiographic Outcome After PTCA.  JACC 1997;29(2):277 A
5.	Gibson CM, Rizzo MJ, McLean, Dotani I, Goel M, Ryan KA, Marble SJ, Al-Mousa EN, Daley WL, Dodge T.  The  TIMI Frame Count and  Restenosis : Faster is Better JACC 1997;29(2):201A
6.	Gibson CM, Rizzo MJ, Ryan KA,  McLean C, Marble SJ, Dotani I, Goel M, Al-Mousa EN, Daley WL, Dodge T.  The Use of PTCA Guidewire to Measure Artery Length and the TIMI Frame Count to Measure Time as a Method of Calculating Coronary Velocity( Length /Time & Coronary Blood Flow).  JACC 1997;29(2):18A
7.	Dodge T, Goel M, Al-Mousa EN, Daley WL, Brown G, Gibson CM.  In Vivo Validation of a New Three Dimensional Vector Model of Distance in Human Coronary Arteries.   JACC 1997;29(2):35A
8.	Gibson CM, Marble SJ, Rizzo MJ, Ryan KA, McLean C, Sparano AM,  Moynihan J, Al-Mousa EN, Dodge T.  Pooled Analysis of Primary Stenting in Acute MI in 1,357 Patients.  JACC 1997;29(2):18A
9.	Gibson CM, Rizzo MJ, Ryan KA, McLean C, Sparano AM,  Moynihan J, Al-Mousa EN, Dodge T.  Multivariable Model of Coronary Flow at 90 Minutes Following Thrombolysis.   Circulation 1997;96(8):I-340
10.	Al-Mousa E, Cannon L, Senior D, Feit F, Attubato M, Rosenberg J, ODonell C, Ryan K, Sparano AM, Gibson CM.  Directional Atherectomy Normalizes Guide wire Velocity in the Intermediate Vessel Atherectomy Trial ( IVAT). Circulation 1997;96(8):I-648
11.	Dodge T, Sparano AM, Ryan KA, McLean C, Ralston A, Al-Mousa EN, Daley WL. Best Angiographic Views  to Minimize  Coronary Artery Foreshortening.    Circulation 1997;96(8):I-78
Grand Rounds and invited Presentations:'
1.	Platelet Glycoprotein IIb/IIIa in Cardiology.  Cardiology Grand Rounds, West Roxbury VA Medical center, Harvard Medical School, Boston,  Massachusetts, USA March 1997
2.	Valvular Heart Disease.  Speciality Hospital, Amman, Jordan 1998.
3.	Update on Acute MI.  Jordan University Hospital medical grand round. 1998
4.	State of the art on Lipid therapy. Jordan University Hospital medical grand round. 1999
5.	Contemporary Management of Acute Coronary Syndromes.  Saddam Heart Center.  Baghdad, Iraq 1999
6.	Statins Overview.  Bristol Myers Squib invited lecturer.  Jordan Lipid and hypertension society.  Amman, Jordan 2000.
7.	Heart Protection Study.  MSD invited lecturer.  Amman, Jordan 2001
8.	Statins: from bench to bedside.  Bristol Myers Squib symposium- keynote speaker.  First Pan Arab internal medicine conference.  Amman , Jordan 2002
9.	NCEP 3 Guidelines- New Perspectives.  Experts Meeting-Novartis Symposium.  Beirut, Lebanon 2002
10.	Hypertension Management, Combination Therapy.  Novartis Symposium.  Dead Sea, Jordan 2002
11.	LIPS Study.  Novartis Invited Lecture. Amman, Jordan 2002
12.	Survey of Jordanian Physicians Attitude towards Dyslipidemia.  Sixth Jordanian Cardiac Society meeting.  Amman, Jordan. October 2002
13.	Overview of ARBs.  Novartis invited lecturer. Sharm Al-Sheikh, Egypt. February 2003 
14.	PROSPER study.  Bristol Myers Squib invited lecturer. Amman, Jordan. March 2003
15.	Quality Control of Blood Pressure. BoehrInger Ingelheim invited lecturer. Amman, Jordan. March 2003. Petra, Jordan.  March and April 2004
16.	Hypertension: clinical aspects and tips for management.  Astra-Zeneca invited lecturer.  Petra, Jordan.  May 2003
17.	Prove It Study,  Bristol Myers Squib invited lecturer. Amman, Jordan. March 2004
18.	 Founder and Moderator of the Monthly City Wide Cardiac Catheterization Conference 8 / 2003- present.  Amman  Jordan
19.	 LIFE Study,  Losartan Launch Symposium. Private health care sector lecture. Khartoum, Sudan. March 2004
20.	 EUROPA study.  Servier Symposium- keynote speaker.  Second Pan Arab Internal Medicine Conference.  Amman, Jordan. April 2004
21.	Coronary Ectasia in Jordanians.  Seventh Jordanian Cardiac Society meeting.  Amman, Jordan. June 2004
22.	The VALUE study, Novartis invited lecturer.  Amman, Jordan.  10/2004
23.	The Moses study.  Solvay invited lecturer. Amman, Jordan.  10/2004
24.	Overview of Modern Thrombolytic Therapy.  Nairobi Hospital. Nairobi, Kenya. 10/2004
25.	Hypertension Overview. Kenyatta Hospital Medical Grand Round. Nairobi, Kenya. 10/2004
26.	Sustained control of Blood Pressure.  Micardis Plus Launch Symposium-Keynote Speaker. Nairobi, Kenya. 10/2004
27.	Overview of ARBs. Qaryounes University. Benghazi, Libya. 2/2005
28.	The Moses study.  Solvay invited lecturer. Beirut. Lebanon  3/2005 and 3/ 2006
29.	Clarity and Commit Trials.  Sanofi- Aventis/Jordan Internal Medicine Society invited lecturer. Al - Istiklal Hospital .  Amman. Jordan 12/2005
30.	Clarity and Commit Trials.  Sanofi- Aventis invited lecturer. Cairo. Egypt. 12/2005
31.	Hypertension in Pregnancy.  Jordan Obstetrics Society Lecture. Amman, Jordan 12/2005
32.	Overview of Recent Statin Trial,  Astra- Zeneca invited lecturer. Amman, Jordan.  4/2006
33.	ASCOT Trial. A new way to target hypertension. Pfizer invited lecturer. Amman, Jordan.  4/2006. 
34.	JOHARTS 4 study.  Eighth Jordanian Cardiac Society meeting.  Amman, Jordan. June 2006
35.	Review of Valsartan evidence. Novartis Diovan Launch Symposium-Keynote Speaker. Damascus and Allepo. Syria 12/2006
36.	Aliskiren, a new Renin inhibitor.  Pre-launch symposium . Novartis Jordan. Dead sea. 11/2007. 
37.	Calcium Channel Blockers revisited- Jerusalem drug company lecture-Amman, Jordan 2/2008
38.	DES Overview- Focus on biodegradable polymers technology- Biomatrix stent,, Biosensors invited lecture. 3/2008. 
39.	New pathways in hypertension. Novartis invited speaker. Beijing, China,4/2008
40.	CLOPLAV pharmacodynamic study, first study in Jordan with head to head comparison 
41.	Numerous lectures for special courses on ACLS, critical care, cardiac diseases in pregnancy, preoperative cardiac assessment...   1997-present.